At Tri-Con, UCSF's Charles Chiu discussed validation of a metagenomic NGS test as well as a new project to develop an RNA sequencing panel for Lyme disease.
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
NanoString said its sequencing technology harnesses its expertise in optical barcodes and that it would develop it for clinical use to complement its existing products.
The companies will work together to seek FDA clearance or approval for a number of biomarker and immuno-oncology assay kits for use on the MiSeqDx.
The company is developing a non-invasive test that analyzes only a small area of the genome to infer overall tumor mutational load to help guide immunotherapy use.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.